Evaluation of Hypoglycemia in Neonates of Women at Risk for Late Preterm Delivery : An Antenatal Late Preterm Steroids Trial Cohort Study
Thieme. All rights reserved..
OBJECTIVE: In the antenatal late preterm steroids (ALPS) trial betamethasone significantly decreased short-term neonatal respiratory morbidity but increased the risk of neonatal hypoglycemia, diagnosed only categorically (<40 mg/dL). We sought to better characterize the nature, duration, and treatment for hypoglycemia.
STUDY DESIGN: Secondary analysis of infants from ALPS, a multicenter trial randomizing women at risk for late preterm delivery to betamethasone or placebo. This study was a reabstraction of all available charts from the parent trial, all of which were requested. Unreviewed charts included those lost to follow-up or from sites not participating in the reabstraction. Duration of hypoglycemia (<40 mg/dL), lowest value and treatment, if any, were assessed by group. Measures of association and regression models were used where appropriate.
RESULTS: Of 2,831 randomized, 2,609 (92.2%) were included. There were 387 (29.3%) and 223 (17.3%) with hypoglycemia in the betamethasone and placebo groups, respectively (relative risk [RR]: 1.69, 95% confidence interval [CI]: 1.46-1.96). Hypoglycemia generally occurred in the first 24 hours in both groups: 374/385 (97.1%) in the betamethasone group and 214/222 (96.4%) in the placebo group (p = 0.63). Of 387 neonates with hypoglycemia in the betamethasone group, 132 (34.1%) received treatment, while 73/223 (32.7%) received treatment in placebo group (p = 0.73). The lowest recorded blood sugar was similar between groups. Most hypoglycemia resolved by 24 hours in both (93.0 vs. 89.3% in the betamethasone and placebo groups, respectively, p = 0.18). Among infants with hypoglycemia in the first 24 hours, the time to resolution was shorter in the betamethasone group (2.80 [interquartile range: 2.03-7.03) vs. 3.74 (interquartile range: 2.15-15.08) hours; p = 0.002]. Persistence for >72 hours was rare and similar in both groups, nine (2.4%, betamethasone) and four (1.9%, placebo, p = 0.18).
CONCLUSION: In this cohort, hypoglycemia was transient and most received no treatment, with a quicker resolution in the betamethasone group. Prolonged hypoglycemia was uncommon irrespective of steroid exposure.
KEY POINTS: · Hypoglycemia was transient and approximately two-thirds received no treatment.. · Neonates in the ALPS trial who received betamethasone had a shorter time to resolution than those with hypoglycemia in the placebo group.. · Prolonged hypoglycemia occurred in approximately 2 out of 100 late preterm newborns, irrespective of antenatal steroid exposure.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2023 |
---|---|
Erschienen: |
2023 |
Enthalten in: |
Zur Gesamtaufnahme - volume:40 |
---|---|
Enthalten in: |
American journal of perinatology - 40(2023), 5 vom: 01. Apr., Seite 532-538 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Gyamfi-Bannerman, Cynthia [VerfasserIn] |
---|
Links: |
---|
Themen: |
9842X06Q6M |
---|
Anmerkungen: |
Date Completed 22.03.2023 Date Revised 02.04.2023 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1055/s-0041-1729561 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM325932557 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM325932557 | ||
003 | DE-627 | ||
005 | 20231225193508.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2023 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1055/s-0041-1729561 |2 doi | |
028 | 5 | 2 | |a pubmed24n1086.xml |
035 | |a (DE-627)NLM325932557 | ||
035 | |a (NLM)34044454 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Gyamfi-Bannerman, Cynthia |e verfasserin |4 aut | |
245 | 1 | 0 | |a Evaluation of Hypoglycemia in Neonates of Women at Risk for Late Preterm Delivery |b An Antenatal Late Preterm Steroids Trial Cohort Study |
264 | 1 | |c 2023 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 22.03.2023 | ||
500 | |a Date Revised 02.04.2023 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Thieme. All rights reserved. | ||
520 | |a OBJECTIVE: In the antenatal late preterm steroids (ALPS) trial betamethasone significantly decreased short-term neonatal respiratory morbidity but increased the risk of neonatal hypoglycemia, diagnosed only categorically (<40 mg/dL). We sought to better characterize the nature, duration, and treatment for hypoglycemia | ||
520 | |a STUDY DESIGN: Secondary analysis of infants from ALPS, a multicenter trial randomizing women at risk for late preterm delivery to betamethasone or placebo. This study was a reabstraction of all available charts from the parent trial, all of which were requested. Unreviewed charts included those lost to follow-up or from sites not participating in the reabstraction. Duration of hypoglycemia (<40 mg/dL), lowest value and treatment, if any, were assessed by group. Measures of association and regression models were used where appropriate | ||
520 | |a RESULTS: Of 2,831 randomized, 2,609 (92.2%) were included. There were 387 (29.3%) and 223 (17.3%) with hypoglycemia in the betamethasone and placebo groups, respectively (relative risk [RR]: 1.69, 95% confidence interval [CI]: 1.46-1.96). Hypoglycemia generally occurred in the first 24 hours in both groups: 374/385 (97.1%) in the betamethasone group and 214/222 (96.4%) in the placebo group (p = 0.63). Of 387 neonates with hypoglycemia in the betamethasone group, 132 (34.1%) received treatment, while 73/223 (32.7%) received treatment in placebo group (p = 0.73). The lowest recorded blood sugar was similar between groups. Most hypoglycemia resolved by 24 hours in both (93.0 vs. 89.3% in the betamethasone and placebo groups, respectively, p = 0.18). Among infants with hypoglycemia in the first 24 hours, the time to resolution was shorter in the betamethasone group (2.80 [interquartile range: 2.03-7.03) vs. 3.74 (interquartile range: 2.15-15.08) hours; p = 0.002]. Persistence for >72 hours was rare and similar in both groups, nine (2.4%, betamethasone) and four (1.9%, placebo, p = 0.18) | ||
520 | |a CONCLUSION: In this cohort, hypoglycemia was transient and most received no treatment, with a quicker resolution in the betamethasone group. Prolonged hypoglycemia was uncommon irrespective of steroid exposure | ||
520 | |a KEY POINTS: · Hypoglycemia was transient and approximately two-thirds received no treatment.. · Neonates in the ALPS trial who received betamethasone had a shorter time to resolution than those with hypoglycemia in the placebo group.. · Prolonged hypoglycemia occurred in approximately 2 out of 100 late preterm newborns, irrespective of antenatal steroid exposure | ||
650 | 4 | |a Multicenter Study | |
650 | 4 | |a Journal Article | |
650 | 4 | |a Research Support, N.I.H., Extramural | |
650 | 7 | |a Betamethasone |2 NLM | |
650 | 7 | |a 9842X06Q6M |2 NLM | |
700 | 1 | |a Jablonski, Kathleen A |e verfasserin |4 aut | |
700 | 1 | |a Blackwell, Sean C |e verfasserin |4 aut | |
700 | 1 | |a Tita, Alan T N |e verfasserin |4 aut | |
700 | 1 | |a Reddy, Uma M |e verfasserin |4 aut | |
700 | 1 | |a Jain, Lucky |e verfasserin |4 aut | |
700 | 1 | |a Saade, George R |e verfasserin |4 aut | |
700 | 1 | |a Rouse, Dwight J |e verfasserin |4 aut | |
700 | 1 | |a Clark, Erin A S |e verfasserin |4 aut | |
700 | 1 | |a Thorp, John M |c Jr |e verfasserin |4 aut | |
700 | 1 | |a Chien, Edward K |e verfasserin |4 aut | |
700 | 1 | |a Peaceman, Alan M |e verfasserin |4 aut | |
700 | 1 | |a Gibbs, Ronald S |e verfasserin |4 aut | |
700 | 1 | |a Swamy, Geeta K |e verfasserin |4 aut | |
700 | 1 | |a Norton, Mary E |e verfasserin |4 aut | |
700 | 1 | |a Casey, Brian M |e verfasserin |4 aut | |
700 | 1 | |a Caritis, Steve N |e verfasserin |4 aut | |
700 | 1 | |a Tolosa, Jorge E |e verfasserin |4 aut | |
700 | 1 | |a Sorokin, Yoram |e verfasserin |4 aut | |
700 | 1 | |a VanDorsten, J Peter |e verfasserin |4 aut | |
700 | 0 | |a Eunice Kennedy Shriver National Institute of Child Health Human Development Maternal-Fetal Medicine Units Network |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t American journal of perinatology |d 1993 |g 40(2023), 5 vom: 01. Apr., Seite 532-538 |w (DE-627)NLM013020544 |x 1098-8785 |7 nnns |
773 | 1 | 8 | |g volume:40 |g year:2023 |g number:5 |g day:01 |g month:04 |g pages:532-538 |
856 | 4 | 0 | |u http://dx.doi.org/10.1055/s-0041-1729561 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 40 |j 2023 |e 5 |b 01 |c 04 |h 532-538 |